نتایج جستجو برای: exemestane

تعداد نتایج: 576  

Journal: :Oncology 2001
A Hamilton M Volm

Anastrozole (Arimidex), letrozole (Femara), and exemestane (Aromasin) are members of the third generation of aromatase inhibitors that has now replaced aminoglutethimide (Cytadren), the progestins, and tamoxifen (Nolvadex) as the hormonal therapy of choice in estrogen-receptor-positive, postmenopausal, metastatic breast cancer. This article will review the role of aromatase in the pathogenesis ...

2015
Saranya Chumsri

Aromatase is an enzyme that converts testosterones to estrogens. Inhibition of this enzyme has been shown to have several clinical utilities in breast cancer. Currently, there are three aromatase inhibitors (AIs) in clinical use, namely anastrozole, letrozole, and exemestane. AIs have been used in various clinical settings for breast cancer, ranging from chemoprevention in breast cancer to trea...

Journal: :Duodecim; laaketieteellinen aikakauskirja 2002
Aman U Buzdar

Recent advances have been made in the hormonal treatment of breast cancer with the advent of third-generation aromatase inhibitors (anastrozole, letrozole, and exemestane). These newer agents have substantial antitumor activity and appear to be as effective as tamoxifen, with fewer adverse effects. Recent reports indicate that anastrozole is more effective than tamoxifen as adjuvant endocrine t...

2013
Kala Visvanathan

Breast cancer is now the most common cancer diagnosedworldwide. There is substantial evidence that 5 years of treatment with chemopreventive agents, such as tamoxifen, raloxifene, and exemestane, can reduce the incidence of hormone-positive cancers in high-risk women. Nevertheless, the uptake of these agents has been poor, even in women with atypical hyperplasia and lobular carcinoma in situ (L...

Journal: :Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013
Kala Visvanathan Patricia Hurley Elissa Bantug Powel Brown Nananda F Col Jack Cuzick Nancy E Davidson Andrea Decensi Carol Fabian Leslie Ford Judy Garber Maria Katapodi Barnett Kramer Monica Morrow Barbara Parker Carolyn Runowicz Victor G Vogel James L Wade Scott M Lippman

PURPOSE To update the 2009 American Society of Clinical Oncology guideline on pharmacologic interventions for breast cancer (BC) risk reduction. METHODS A systematic review of randomized controlled trials and meta-analyses published from June 2007 through June 2012 was completed using MEDLINE and Cochrane Collaboration Library. Primary outcome of interest was BC incidence (invasive and noninv...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید